Kensei Yamaguchi

1 ta ish

Japanese Foundation For Cancer Research

1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

   Yelena Y. Janjigian, Kohei Shitara, Markus Moehler +26

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.596966